The Stevanato Group has announced that it will manufacture pre-fillable glass syringes for Recipharm’s Resyca pre-filled syringe soft mist inhalers for the delivery of biologics. According to Stevanato Group, the interior of the Alba glass syringe has a silicone oil-based coating for improved particle release.
The Resyca SMI is the product of a 2020 joint venture between Recipharm and Medspray. At DDL 2022, Resyca Chief Technology Officer Wilbur de Kruijf discussed the use of SMIs for as a solution for delivery of inhaled biologics, and the company says that its devices are appropriate for use with inhaled mAbs, phages, and mRNA.
Resyca General Manager and Chief Operational Officer Bernhard Muellinger said, “By leveraging Stevanato Group’s integrated capabilities, from plastic injection molding and assembly capabilities to comprehensive scientific and analytical support services, we will be able to offer a turnkey solution, and accelerate and de-risk our pharmaceutical customers’ development programs. This is particularly true for novel inhaled biological products.”
Stevanato Group CEO Franco Moro commented, “Creating a network of strategic collaboration partners is an important element of our long-term strategy to match customers’ needs and address self-administration trends in patient care with user-friendly drug delivery devices that provide variable and accurate dosing. This agreement marks another key step in broadening our high-value solutions and integrated capabilities as we continue to diversify and enhance our presence in the drug delivery market of pen injectors, auto-injectors, inhalers, and wearable pods.”
Read the Stevanato Group press release.
